A polymerase chain reaction (PCR) assay that detects Borrelia burgdorferi DNA in cerebrospinal fluid (CSF) was evaluated as a diagnostic test for acute or chronic Lyme neuroborreliosis. In one laboratory, 102 samples were tested blindly, and 40 samples were retested in a second laboratory. In the first laboratory, B. burgdorferi DNA was detected in CSF samples in 6 (38%) of 16 patients with acute neuroborreliosis, 11 (25%) of 44 with chronic neuroborreliosis, and none of 42 samples from patients with other illnesses. There was a significant correlation between PCR results and the duration of previous intravenous antibiotic therapy. The overall frequency of positive results was similar in the second laboratory, but concordance between the laboratories and among primer-probe sets was limited because many samples were positive with only one primer-probe set. Thus, PCR testing can sometimes detect B. burgdorferi DNA in CSF in patients with acute or chronic neuroborreliosis, but with current methods, the sensitivity of the test is limited.
meningoradiculitis [4] and not from those with later neurologic manifestations of the disorder. It has been hoped that the detection of B. burgdorferi DNA by polymerase chain reaction (PCR) may serve as a substitute for culture in patients with Lyme disease.
Previous studies using PCR to detect B. burgdorferi DNA in cerebrospinal fluid (CSF) have been done primarily in small numbers of patients with early, acute neuroborreliosis [5] [6] [7] [8] [9] [10] . In these studies, which have used several different probes and techniques, the PCR test had sensitivities of 24%-100%. We previously reported that a PCR assay targeting outer surface protein A (OspA) DNA is highly sensitive and specific for the detection of B. burgdorferi DNA in joint fluid of patients with Lyme arthritis [11] . We report here on the evaluation of this assay as a diagnostic test for the detection of spirochetal DNA in CSF in a large number of patients with acute or chronic Lyme neuroborreliosis.
Methods
Case and control patients. During a l6-year period, CSF samples were collected from 60 patients in the Lyme disease clinics at Yale-New Haven Hospital (1977 -1987) or New England Medical Center (1987 -1993) who met objective criteria for acute or chronic neuroborreliosis [12] . All 60 patients had characteristic manifestations of Lyme disease before onset of neurologic symptoms, and they had elevated levels of IgM (;=:1:200) or IgG (;=: 1:800) antibody to B. burgdorferi in serum, determined by ELISA. Of the 60 patients, 16 had acute neurologic manifestations of the disorder: 14 had meningitis with headache, mild neck stiffness, CSF pleocytosis, and intrathecal antibody production to B. burgdorferi, and 2 had facial palsy or radiculoneuropathy alone without CSF abnor-malities. The remaining 44 patients had chronic neurologic manifestations of the disorder: 29 had a subacute encephalopathy manifested primarily by memory impairment and an abnormal eSF analysis showing pleocytosis, elevated total protein, or intrathecal antibody production; 3 had encephalomyelitis with spastic parapareses and an abnormal CSF analysis; and 12 had symptoms of a sensory polyneuropathy with electrophysiologic evidence of an axonal polyneuropathy.
During the same l6-year period, CSF analyses were done on 22 patients in the Lyme disease clinics who were seronegative and had no history of Lyme disease. Their CSF samples were collected, processed, and stored in the same way as those from patients with Lyme disease. An additional 20 control CSF samples were obtained from patients who were evaluated for possible herpes simplex virus encephalitis at the Mayo Clinic.
In all patients, CSF samples were divided into multiple aliquots and frozen at -70°e. In most cases, the aliquot used for testing was not thawed or opened before this study. All samples, including the 20 from the Mayo Clinic, were coded and blinded in the first laboratory. In both laboratories, the persons doing the PCR assays were not aware of the clinical status of the samples. Similarly, clinical data were collected from the charts of all patients without knowledge of the results of PCR assays.
peR assay. CSF samples from case and control patients were processed simultaneously in a blinded manner, as described [11] . Briefly, DNA was isolated from 100 J.LL of CSF, and the DNA extract was resuspended in 30 J.LL of ultrapure water. A 5-J.LL aliquot from this suspension was amplified with primer-probe set 1, which targets base pairs 788-943 at the 3' end of the 50-kb plasmid of B. burgdorferi that encodes OspA [11] . This primerprobe set detects most strains of B. burgdorferi from New England. A second 5-J.LL aliquot was amplified with primer-probe set 2, which targets base pairs 149-343 at the 5' end of the ospA gene [11] . This set detects all North American and European isolates tested to date, with the exception of rare natural isolates that lack the 50-kb plasmid. Amplification consisted of 45 cycles of denaturation at 94°C for 45 s, annealing at 50°C for 45 s, and extension at 72°C for 1 min. The cycles were preceded by a 4-min phase at 94°C and followed by a final 7-min phase at 72°e. Amplified products were resolved by 4% agarose gel electrophoresis and blotted onto nylon membranes, which were hybridized with the appropriate 32p -5' end -labeled internal oligonucleotide probe [11] and exposed to film for 4-72 h.
Control samples included with each amplification assay were as follows: samples with DNA extracted from control patients, 1-3 blank samples containing 5 J.LL of water substituted for DNA, and a positive sample containing 60-600 pg of total B. burgdorferi DNA. A random group of 18 samples from Lyme disease patients in which B. burgdorferi DNA was not detected was tested for inhibitors of the PCR reaction. For these tests, 600 pg of B. burgdorferi DNA was added to 100 J.LL of each sample, and DNA was detected using primer-probe set 1.
In an effort to determine the reliability of testing, 40 case and control samples in which enough CSF remained were tested again in a second laboratory using primer-probe sets 3 and 4, as described [13] . After the initial tests, the samples were frozen at -20 0 e , and they were thawed again for retesting. Primer set 3 targeted the same primer sequences of ospA for amplification as set 2 but used a different internal probe for detection; set 4 targeted a portion of ospB. Amplification products were detected with chemiluminescent, full-length internal probes, constructed according to the manufacturer's instructions (Amersham, Arlington Heights, IL).
Statistical analysis. The similarity of groups was compared by X 2 test, and the distribution of values among the groups was compared by Wilcoxon rank sum test. Concordance among test results was calculated with K values according to the following formula:
Results PCR. B. burgdorferi DNA was detected in CSF samples in 6 (38%) of the 16 patients with acute neuroborreliosis and in 11 (25%) of the 44 patients with chronic neuroborreliosis (table 1) . In contrast, none of the 22 identically processed control CSF samples, none of the additional 20 control CSF samples, and none of the blank control samples had positive PCR results. Of the 17 samples with positive PCR results, 11 had positive results when tested with primer-probe set 1, and 10 had positive results with set 2; only 4 had positive results with both primer-probe sets. Therefore, the concordance of results with the 2 primer-probe sets was limited (K = .25). In inhibition assays, only 2 of 18 randomly selected negative samples from Lyme disease patients still had negative results when B. burgdorferi DNA was artificially added to these samples. Thus, inhibitors of PCR amplification in CSF seemed to be an unusual cause of negative results.
When a subset of 40 case and control samples was retested in a second laboratory, 2 (50%) of the 4 samples from patients with acute neuroborreliosis had positive PCR results, as did 2 (13 %) of the 16 samples from patients with chronic neuroborreliosis; all 20 control samples were negative (table 1). Only 1 of the 4 positive samples had positive results with both primer-probe sets (sets 3 and 4) used in that laboratory. Of the 8 samples tested that had initially been positive in the first laboratory, 3 were positive in the second laboratory, and 1 additional sample from a patient with chronic neuroborreliosis was positive in that laboratory. Thus, in the two laboratories, the overall frequency of positive results was not significantly different, but the concordance was limited (K = .26) because many samples were positive with only one primer-probe set.
Clinical correlations. When the clinical data for the 60 patients with acute or chronic neuroborreliosis were analyzed according to the PCR results from the first laboratory, the median age, sex ratio, duration of disease, and antibody responses to B. burgdorferi in serum or CSF were similar in PCRpositive and PCR-negative patients (table 2) . For example, in the patients with acute neuroborreliosis, the median duration from disease onset to lumbar puncture was 3 months among those with positive PCR results and 2 months among those with negative PCR results; in those with chronic neuroborreliosis, the median duration of disease before testing was 7.3 years among PeR-positive patients and 5 years among PCR- negative patients. However, the PCR-positive and PCR-negative patients differed in the length of antibiotic treatment prior to testing. Three (23%) of 13 untreated patients and 12 (48%) of25 patients who had received 1-27 days of antibiotic therapy before testing had positive PCR results, whereas only 2 (9%) of 22 patients who had received> 1 month of antibiotics before testing had positive results (P = .01). Both of these PCRpositive patients had been given 2 months of oral antibiotics and 2 weeks of intravenous therapy. Among the 18 patients who had received intravenous antibiotics before testing, the median duration oftreatment in PeR-positive patients (14 days) was significantly less than in PCR-negative patients (30 days) (P = .01). No patient who had received> 2 weeks of intravenous therapy had a positive PCR result. Eight patients with positive PCR results were subsequently treated with intravenous ceftriaxone, 2 g/day for 30 days, and lumbar punctures were repeated 3-12 months later. All 8 patients had improvement in their signs and symptoms, and they had negative PCR results in follow-up tests.
Discussion
In this study, B. burgdorferi DNA was detected in CSF in 38% of patients with acute neuroborreliosis and 25% of those with chronic neuroborreliosis. These percentage frequencies are at the low end compared with those in previous reports of patients with neuroborreliosis [5] [6] [7] [8] [9] [10] . Moreover, many samples in this study were positive with only one primer-probe set, and therefore, concordance among sets and between laboratories was limited. There are two possible explanations for the limited concordance among samples in this study. First, contamination of some samples during initial tests may have caused false-positive results. However, when the results of blinded determinations were analyzed, the PCR results correlated with the duration of previous intravenous antibiotic therapy, and all control samples were negative. This distribution of results would be unlikely if the samples had been contaminated.
The alternate possibility is that the concentration of spirochetal plasmids in any given 100-J.tL aliquot of CSF may have been close to the limits of detectability. Furthermore, the freeze-thaw cycle that was necessary for repeat testing of samples in the second laboratory may have caused further degradation of spirochetal DNA. In previous studies in which serial dilutions of known numbers of spirochetes were tested with the OspA primer-probe sets used here, 1 spirochetal genome equivalent could be detected, but 10 or more genome equivalents were required for consistent results [13] . Accordingly, in neuroborreliosis, 100-J.tL CSF samples may often contain no more than 1-10 ospA plasmids. Thus, we believe that low numbers or absence of spirochetal plasmids in CSF is a more likely explanation for the insensitivity and limited reproducibility of the CSF assay than contamination of samples during testing.
Does the detection of B. burgdorferi DNA in CSF mean that the patient has active or latent spirochetal infection of the nervous system? In previous studies of joint fluid in patients with Lyme arthritis [11, 14] and in the current study, ospA DNA was detected primarily in untreated or inadequately treated patients with clinically active disease. When the current patients who initially had positive results were tested after l-rnonth courses of intravenous ceftriaxone, the results were negative. Likewise, in studies of murine B. burgdorferi infection, PCR results were almost always negative within 2~-4 weeks after treatment with ceftriaxone [15] . Thus, it seems likely that the detection of ospA DNA in CSF indicates the presence of viable spirochetes in the nervous system. Furthermore, the significant correlation in the current study between PCR results and the duration of intravenous antibiotic therapy (but not oral therapy) supports clinical observations that neuroborreliosis can usually be treated successfully with 2-to 4-week courses of intravenous therapy [2, 3] .
Patients may develop chronic neuroborreliosis years after early manifestations of Lyme disease [4] . In the current study, B. burgdorferi DNA was detected in such patients a median of 7.3 years and as long as 27 years after disease onset. Although only 4 samples in this study were positive with more than one primer pair, this includes the sample obtained 27 years after disease onset, which was positive in both laboratories, and a sample obtained 7 years after disease onset. This provides the best evidence to date that the Lyme disease spirochete may persist actively or latently in the nervous system for years. This prolonged disease course, with long periods of active and latent infection, is reminiscent of tertiary neurosyphilis.
In summary, peR testing can detect B. burgdorferi DNA in CSF in some patients with acute or chronic neuroborreliosis. This method represents an advance over culture, which is usually negative in patients with neuroborreliosis. However, for the PCR test to be of routine diagnostic value, greater sensitivity is needed. First, testing larger volumes of CSF and better sample preparation than was possible in this retrospective study are likely to help. This may include concentrating or aggregating spirochetal DNA from 1 to 10 mL of CSF and prompt testing of samples without freeze-thaw cycles. For the present, a positive PCR test may be a useful adjunct in the diagnosis of acute or chronic neuroborreliosis in combination with appropriate clinical, serologic, and neurologic test results.
The Jarisch-Herxheimer reaction (JHR) observed after antibiotic treatment of relapsing fever caused by Borrelia recurrentis is associated with the systemic appearance of cytokines. The decrease of cytokine production and block of JHR was attempted by administering pentoxifylline prior to antibiotic treatment. Fifteen patients with confirmed relapsing fever were infused intravenously with pentoxifylline 90 min before intramuscular injection of penicillin; 4 patients were not treated with pentoxifylline. All patients developed JHR to varying degrees. Treatment with pentoxifylline failed to prevent fever, increase in pulse, respiration, or blood pressure, or decrease in white blood cell count. No reduction of circulating levels of tumor necrosis factor, interleukin 6, or interleukin-8 was observed with pentoxifylline treatment. Pentoxifylline did not prevent clearance of the B. recurrentis spirochetes. Thus, pentoxifylline treatment of patients with relapsing fever fails to prevent or diminish JHR or the associated cytokine release observed after appropriate antibiotic treatment.
The Jarisch-Herxheimer reaction (JHR) is a severe systemic reaction observed after treatment of spirochete infections, although it can be observed after treatment of other bacterial infections. The reaction consists of a rise in temperature, a decrease in white blood cell count, and a rise in pulse and respiration rates. While it occurs after treatment of many spirochete infections, the most severe reaction occurs after treatment of relapsing fever [1] .
Relapsing fever is due to the bloodborne spirochete, Borrelia recurrentis. The spirochete is spread from host to host by ticks or lice and is endemic in eastern Africa. The disease results in recurring fevers with relapses every 3-5 days. Relapsing fever carries a high mortality rate if left untreated; however, standard antibiotic therapy induces JHR in up to 40% of treated patients [2] .
We have previously reported that JHR is associated with the systemic release of cytokines [3] . Many reports have implicated the acute production of cytokines as the causative factors for the altered pathophysiology observed in several diseases. In this study, we sought to reduce the production of cytokines by pretreating patients with pentoxifylline, which has been re-
